

## **REMARKS**

### **Election/Restrictions**

The Office has restricted the amended claims into 11 distinct inventions, restricted on nucleotide sequence (SEQ ID NOs:1, 2, 3, 24, 25, 26, 37, 38, 39, 51, 52), arguing that each sequence is chemically distinct and separable invention. Applicants elect SEQ ID NO:24 without traverse. Applicants have amended claim 1 in part to be restricted to SEQ ID NO:24, and further amended the claim to a nucleic acid sequence having at least 95% sequence identity to the sequence of SEQ ID NO:24. Support for the sequence identity limitation can be found on page 21, lines 29-32. No new matter has been added as a result of this amendment.

**CONCLUSION**

Applicants respectfully request timely allowance of the pending claims. Should the Office feel that there are any issues outstanding after consideration of the response; the Office is invited to contact the Applicant's undersigned representative to expedite prosecution.

CHROMATIN, INC.

3440 South Dearborn Street, Suite 010

Chicago, Illinois 60616

Dated:

Direct phone calls to:

Respectfully submitted,

/Gregory M. Zinkl/

Gregory M. Zinkl, Ph.D.

US Registration No. :48,492

Attorney for Applicants

October 6, 2010

(312) 235.3621